These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26951615)

  • 1. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
    Flack KF; Desai J; Kolb JM; Chatterjee P; Wallentin LC; Ezekowitz M; Yusuf S; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Clin Gastroenterol Hepatol; 2017 May; 15(5):682-690. PubMed ID: 27765728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
    Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
    Sherid M; Sifuentes H; Sulaiman S; Samo S; Husein H; Tupper R; Spurr C; Sridhar S
    Korean J Gastroenterol; 2015 Apr; 65(4):205-14. PubMed ID: 25896154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Yen KC; See LC; Chang SH; Wu LS; Lee HF; Tu HT; Yeh YH; Kuo CT
    Stroke; 2016 Feb; 47(2):441-9. PubMed ID: 26732563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study).
    Sam C; Massaro JM; D'Agostino RB; Levy D; Lambert JW; Wolf PA; Benjamin EJ;
    Am J Cardiol; 2004 Oct; 94(7):947-51. PubMed ID: 15464686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.
    Ellis MH; Neuman T; Bitterman H; Dotan SG; Hammerman A; Battat E; Eikelboom JW; Ginsberg JS; Hirsh J
    Eur J Intern Med; 2016 Sep; 33():55-9. PubMed ID: 27296588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
    Jiang H; Jiang Y; Ma H; Zeng H; Lv J
    Clin Cardiol; 2021 Sep; 44(9):1208-1215. PubMed ID: 34302375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY; Li X; Wong ICK; Man KKC; Lip GYH; Leung WK; Siu CW; Chan EW
    J Thromb Haemost; 2017 Oct; 15(10):1923-1933. PubMed ID: 28748652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
    Abe J; Umetsu R; Kato Y; Ueda N; Nakayama Y; Suzuki Y; Suzuki T; Nagasawa H; Kinosada Y; Nakamura M
    Int J Med Sci; 2015; 12(4):312-21. PubMed ID: 25897292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
    Kolb JM; Flack KF; Chatterjee-Murphy P; Desai J; Wallentin LC; Ezekowitz M; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Dig Dis Sci; 2018 Jul; 63(7):1878-1889. PubMed ID: 29582237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
    Shireman TI; Howard PA; Kresowik TF; Ellerbeck EF
    Stroke; 2004 Oct; 35(10):2362-7. PubMed ID: 15331796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.